Philadelphia’s Complex Litigation Center remains crowded with Risperdal cases, but it was litigation over removable blood filters that became the fastest-growing mass tort program at the First Judicial District in 2019.

According to the latest numbers on the court’s mass torts inventory, the number of lawsuits over the IVC, or inferior vena cava, filters nearly doubled since January 2019, but nearly all other mass tort programs in Philadelphia saw minimal or negative growth. Still, because of the lingering effects of a flood of lawsuits into the Risperdal litigation in 2017, the total number of cases pending in the court’s Complex Litigation Center remains almost as high as it’s ever been.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]